Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Acquisitions (2016 - 2024)

Historic Acquisitions for Ligand Pharmaceuticals (LGND) over the last 7 years, with Q4 2024 value amounting to -$92.0 million.

  • Ligand Pharmaceuticals' Acquisitions changed N/A to -$92.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$92.0 million, marking a year-over-year change of. This contributed to the annual value of $10.4 million for FY2023, which is N/A changed from last year.
  • As of Q4 2024, Ligand Pharmaceuticals' Acquisitions stood at -$92.0 million.
  • Over the past 5 years, Ligand Pharmaceuticals' Acquisitions peaked at $378.0 million during Q4 2020, and registered a low of -$92.0 million during Q4 2024.